우리나라 제약기업의 개방형 혁신 유형과 특성에 대한 분석

Open Innovation Modes and Characteristics of the Domestic Pharmaceutical Companies in Korea

This paper investigates the Open Innovation modes and characteristics of the domestic pharmaceutical companies in Korea with analyzing open innovation cases of 43 Korea Innovative Pharmaceutical Companies (KIPC) designated by Korean government. The initial data of alliance involving these companies were collected from the commercial database on the pharmaceutical deals. The alliance data were screened with the criteria derived from the definition of Open Innovation. Total 123 open innovation cases were analyzed by the type of open innovation partner, R&D stages, technology area and open innovation mode (inbound vs outbound). The outbound open innovation was relatively active in the small-sized firms group, the incrementally modified drug technology area and the exploration R&D stage. These characteristics of the Korean pharmaceutical firms’ open innovation can be explained as the small-sized firms tends to pursue the out-licensing strategy in the early stage because of the lack of capabilities for further development while the larger Korean firms mainly depend on the in-licensing strategy.